ADAM (a disintegrin and metalloproteinase) 10 is a key member of the ADAM family of disintegrin and metalloproteinases which process membrane-associated proteins to soluble forms in a process known as 'shedding'. Among the major targets of ADAM10 are Notch, EphrinA2 and CD44. In many cell-based studies of shedding, the activity of ADAM10 appears to overlap with that of ADAM17, which has a similar active-site topology relative to the other proteolytically active ADAMs. The tissue inhibitors of metalloproteinases, TIMPs, have proved useful in the study of ADAM function, since TIMP-1 inhibits ADAM10, but not ADAM17; however, both enzymes are inhibited by TIMP-3. In the present study, we show that, in comparison with ADAM17 and the MMPs (matrix metalloproteinases), the N-terminal domains of TIMPs alone are insufficient for the inhibition of ADAM10. This knowledge could form the basis for the design of directed inhibitors against different metalloproteinases.
INTRODUCTION
The ADAM (a disintegrin and metalloproteinase) family consists of modular type I transmembrane proteins that contain a metalloproteinase and a disintegrin-like domain and are members of the metzincin superfamily [other members include MMPs (matrix metalloproteinases) and ADAMTSs (ADAMS with thrombospondin motifs)]. To date, 13 catalytically active ADAMs have been identified in the human genome. An interesting feature of the ADAMs is that they are involved in proteolytic activity, including the 'shedding' of membrane anchored proteins and also in cellular adhesion [1, 2] .
The proteolytic activities of the MPs [metalloproteinases (of the MMP, ADAM and ADAMTS families)] are controlled by their natural inhibitors, the TIMPs (tissue inhibitors of metalloproteinases). To date four variants of human TIMPs exist, TIMP-1-TIMP-4, each showing a different inhibition profile against different MPs. For example, the majority of MMPs are well inhibited by all TIMPs, but TIMP-1 shows very poor inhibitory activity towards the MT-MMPs (membrane-type MMPs) MMP-14, MMP-16, MMP-24 and also towards MMP-19. TIMP-1 is, however, a good inhibitor of ADAM10 [3] . TIMP-3 inhibits the MMPs, ADAM10, ADAM12 and ADAM17 {TACE [TNF (tumour necrosis factor) α converting enzyme]} and the aggrecandegrading enzymes ADAMTS-4 and ADAMTS-5 [4] [5] [6] [7] .
The four TIMPs share a high degree of sequence similarity (40-50 %) and a conserved six-loop structure. The TIMP polypeptide chain folds into a contiguous elongated domain, with the Nterminal domain consisting of the first three loops, containing three out of six disulfide bonds, and the C-terminal part forming two opposing subdomains [11] . To date, the N-terminal domain has been shown to be sufficient for MP inhibition. It contains the major sites of interaction with the catalytic domains of active MPs [8] [9] [10] . The C-terminal subdomain is made up of the remaining 40-60 amino acids. It also contains three disulfide bonds, but its conformation is less well defined [11, 12] . It has been shown to mediate interactions with the catalytic domains of some MMPs and the haemopexin domain of the gelatinases (MMP-2 and MMP-9) [13] .
Among the members of the ADAM family, ADAM17 or TACE has been the most widely studied both in terms of function and TIMP inhibition. ADAM17 is involved in the proteolytic shedding of many cell-surface-associated molecules such as pro-TNFα, Notch, TNFα receptors I and II and ligands of the epidermal growth factor receptor (EGFR) [1, 2] . We have shown that ADAM17 is particularly sensitive to TIMP-3 inhibition and the N-terminal domain, N-TIMP-3, appears to be equally effective [5, 14] .
Our previous studies on TIMP-MP selectivity were successful in converting the N-terminal domains of TIMP-1, TIMP-2 and TIMP-4 into potent inhibitors of ADAM17 by systematic mutagenesis [15] [16] [17] [18] . In the present study, we have examined the inhibition of ADAM10 by TIMPs. ADAM10 not only shows closer sequence similarity and potential structural features with ADAM17 than any other mammalian ADAM, but also is able to cleave TNF-α-based ADAM17 substrates in vitro. In vivo, roles for ADAM10 have been identified in Notch signalling, proteolysis of the cadherins and EphrinA5 [19] [20] [21] . Mice lacking ADAM10 die at day 9.5 with multiple defects in the central nervous system and somites [19] . These phenotypes are related to Notch signalling deficiencies. In addition to neural development, ADAM10 seems to be involved in physiological shedding events Abbreviations used: ADAM, a disintegrin and metalloproteinase; ADAMTS, ADAM with thrombospondin motifs; AP, alkaline phosphatase; DMEM, Dulbecco's modified Eagle's medium; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; FCS, fetal calf serum; HB-EGF, heparin-binding epidermal growth factor; MMP, matrix metalloproteinase; MP, metalloproteinase (of the MMP, ADAM and ADAMTS families); siRNA, short interfering RNA: TACE, tumour necrosis factor α converting enzyme (ADAM17); TIMP, tissue inhibitor of metalloproteinase; N-TIMP, N-terminal domain of TIMP; N-TIMP-1  tace , V4A,TIMP-3ABloop,V69L,T98L,N-TIMP-1; N-TIMP-2  tace , S2T,TIMP-3ABloop,A70S,V71L,N-TIMP-2; N-TIMP-4  tace , S2T,T38P,E39F,K40G,N-TIMP-4; TNF,  tumour necrosis factor. 1 These authors contributed equally to this study. 2 To whom correspondence should be addressed (email gm290@cam.ac.uk).
in the adult brain. Strong evidence suggests that ADAM10 mediates the non-amyloidogenic processing of APP (amyloid precursor protein) [22] . In cell-based studies, ADAM10 and ADAM17 have been shown to carry out the constitutive and regulated 'normal' processing of the cellular prion protein, respectively [23] . These results suggest that defective or misregulated ADAM10 function might contribute to neurodegenerative processes such as Alzheimer's disease and spongiform encephalopathies.
As part of a programme to understand how TIMPs may be engineered to discriminate between MPs, we compared the inhibition of ADAM10 by mutant TIMPs with that of ADAM17. We assessed the inhibition of recombinant soluble human ADAM10 by the N-TIMPs and by the variants that made them active against ADAM17. The kinetic data were compared with the TIMP inhibitory profile towards the activity of native ADAM10 against a physiological substrate, CD44, in a cell-based shedding assay. The results obtained lead us to conclude that, despite their similarities, ADAM10 and ADAM17 are not governed by the same rules where TIMP inhibition is concerned.
EXPERIMENTAL

Materials
All chemicals and reagents were purchased from Sigma Chemicals, unless stated otherwise. Restriction enzymes and Vent R ® DNA polymerase were obtained from New England Biolabs. The soluble ectodomain of human ADAM10 was obtained from R&D Systems, and the recombinant ADAM10 propeptide was prepared from Escherichia coli [24] . ADAM17 was a gift from Dr David Becherer (GlaxoSmithKline Research and Development Inc., Research Triangle Park, NC, U.S.A.). For the kinetic experiments, the fluorimetric substrate Mca-KPLG∼L-Dpa-AR-NH 2 [(7-methoxycoumarin-4-yl)acetyl-Lys-Pro-Leu-Gly∼Leu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH 2 , where ∼ represents the cleavage site] was obtained from Calbiochem. Kinetic assays were performed at 27
• C in fluorescence assay buffer (10 mM CaCl 2 , 50 mM Tris/HCl, pH 7.5, 0.15 M NaCl, 0.05 % Brij-35, 1 % DMSO and 0.02 % sodium azide) with a PerkinElmer LS-50B spectrofluorimeter equipped with thermostatically controlled cuvette holders. The CD44 ELISA kit was purchased from Bender MedSystems.
Antibodies
Anti-ADAM10 (ab-1)-(732-748) rabbit polyclonal antibody was from Calbiochem and anti-ADAM17-(807-823) rabbit polyclonal antibody from Chemicon International. Donkey antirabbit IgG conjugated to horseradish peroxidase was from Jackson ImmunoResearch Laboratories. Anti-β-actin monoclonal antibody was from Abcam, and anti-α-tubulin monoclonal antibody from Sigma.
Cell culture
Human U251 glioblastoma cells were obtained from ECACC (European Collection of Animal Cell Cultures) and maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 2 mM glutamine, 100 IU/ml penicillin, 100 µg/ml strepto- tace (S2T,T38P, E39F,K40G,N-TIMP-4) were prepared from inclusion bodies after expression in E. coli BL21(DE3) cells and refolded as described previously [16] [17] [18] . All proteins were purified by ionexchange chromatography, and their activities were determined by titration against MMP-2 [15] . For cell studies, recombinant TIMPs were prepared as above, dialysed into 50 mM Hepes and 150 mM NaCl (pH 7.4) and passed through endotoxin-removal columns (EndoTrap ® Red, Cambrex Bio Science). Endotoxin levels were assessed before and after treatment using the LAL (Limulus amebocyte lysate) assay (Cambrex Bio Science) according to the manufacturer's protocol.
Electrophoretic techniques
Proteins were analysed by reducing and non-reducing SDS/PAGE on 13 % polyacrylamide gels, followed by staining with Coomassie Brilliant Blue R-250. The presence of single sharp bands with differences in mobility between the two conditions was used to indicate that correct refolding had occurred, in association with active-site titration.
Inhibition constant (K i app ) measurement
Recombinant full-length human ADAM10 was pre-incubated with increasing concentrations of the N-terminal or the fulllength TIMPs. Incubation was performed at room temperature (20 • C) for 3 h before steady-state measurement (V s ). Reactions were initiated by addition of the quenched fluorescent substrate (10 µM). The K i app was determined from the steady-state rates plotted against TIMP concentration. All data were fitted into the tight binding equation using the computer program Grafit to obtain an estimation of K i app values using eqn 1 [16] :
where V o is the rate in the absence of inhibitor, E t is the total enzyme concentration, and I t is the total inhibitor concentration.
Association rate constant (k on ) measurement
Association rate measurements were performed by adding different concentrations of the TIMP mutants to 0.015 nM ADAM10. The rate of inhibition was followed using a continuous fluorimetric assay at 27
• C until the steady state had been reached. The progress curves were analysed using the program Grafit and eqn 2 [17] :
where P is the product concentration, V o is the initial velocity, V s is the steady-state velocity, k is the apparent first-order rate constant of equilibrium between enzyme and TIMP complex, and t is time. k on values were calculated by linear regression of k on TIMP concentrations. U251 cells were seeded in antibiotic-free growth medium in 24-well plates as described above and incubated overnight at 37
• C under 5 % CO 2 . The following day, the cells were transfected with four siRNA duplexes targeting ADAM10 (siGenome individual duplexes, # 1, 3, 4 and 5) or a scrambled control (Dharmacon RNA Technologies) at a final concentration of 100 nM, according to the manufacturer's protocol. The cells were incubated at 37
• C under 5 % CO 2 for 48 h before stimulation with 5 µM ionomycin for 30 min as described above. Cell supernatants were harvested and analysed for soluble CD44 by ELISA. Cell lysates were prepared in 40 µl of cell lysis buffer/well [50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 % (v/v) Triton X-100 and 0.02 % (w/v) sodium azide containing proteinase inhibitors EDTA (5 mM) and proteinase inhibitor cocktail III (1:100) (Calbiochem)] and analysed by Western blotting for ADAM10.
Western blotting
Equivalent amounts of cell lysates were electrophoresed on reducing SDS/8 % PAGE, and the proteins were transferred on to nitrocellulose membranes overnight. ADAM10 was detected using a rabbit polyclonal antibody against human ADAM10 (1:500) and revealed with a secondary antibody conjugated to horseradish peroxidase. Membranes were stripped and reprobed for β-actin as a loading control.
Analysis of RNA expression in U251 cells
U251 cells were seeded at 5 × 10 5 cells/well in six-well plates in antibiotic-free growth medium and incubated overnight at 37
• C. Cells in triplicate wells were transfected as before with a smart pool of the four siRNA oligonucleotides targeting human ADAM10 used in the shedding experiments described previously. The cells were incubated at 37
• C for 96 h and then total RNA was reverse-transcribed and analysed for ADAM10 and ADAM17 gene expression by Taqman ® real-time PCR.
HB-EGF shedding assay
MCF7-HB-EGF-AP cells were seeded at a density of 10 5 cells/ well in DMEM supplemented with 10 % (v/v) FCS and 600 µg/ ml G418. After overnight incubation at 37
• C under 5 % CO 2 , the cells were washed free of serum and incubated in DMEM (300 µl/well) for a further 2 h. Recombinant TIMPs were added at various concentrations for the final 30 min. Shedding was induced by the addition of 100 ng/ml PMA and incubation for a further 5 h at 37
• C. Cell supernatants were harvested and analysed for AP activity as a measure of shed HB-EGF.
AP activity assay
Samples of conditioned medium were incubated for 18 h at 37
• C in the presence of AP substrate (5 mM p-nitrophenylphosphate), 1 mM diethanolamine and 50 µM MgCl 2 dissolved in AP buffer (0.15 M NaCl, 0.5 M Tris/HCl, pH 9.7, and 5 mM EDTA). The absorbance of the coloured reaction product was measured at 420 nm in a microplate reader.
Inhibition of HB-EGF shedding by ADAM17 siRNA
MCF7-HB-EGF-AP cells were seeded into 24-well plates at a density of 10 5 cells/well in antibiotic-free growth medium and were incubated overnight at 37
• C under 5 %, CO 2. The following day, the cells were transiently transfected with siRNA targeting ADAM17 (individual siGenome duplex #4) or a non-targeting control (#1) according to the manufacturer's protocol. The shedding assay was performed at 48 h post-transfection as described previously. Cell lysates were prepared using 40 µl of lysis buffer/well and analysed for ADAM17 protein expression by Western blotting, as described above, using a rabbit polyclonal antibody against human ADAM17 (1:1000). Membranes were stripped and reprobed for α-tubulin as a loading control.
RESULTS
N-TIMPs are poor inhibitors of soluble ADAM10
As a first step in delineating the ADAM10-TIMP interactions, we assessed the interaction of N-TIMPs and their full-length counterparts with the soluble ectodomain of ADAM10 using a quenched fluorescent peptide assay. The binding constants (K i app ) and association rates (k on ), where measurable, are shown in Table 1 . K i app values for TIMP-1 and TIMP-3 against ADAM10 are comparable with those of TIMP-3 and N-TIMP-3 against ADAM17.
In comparison with full-length TIMP-1 and TIMP-3, their N-TIMP counterparts were unable to efficiently inhibit ADAM10. Furthermore, the mutant N-TIMPs, N-TIMP-1 tace , N-TIMP-2 tace and N-TIMP-4 tace engineered to inhibit ADAM17 [15] [16] [17] [18] , had no activity against ADAM10 in this assay (Table 1) . TIMP-2, TIMP-4 and their N-terminal counterparts did not show any detectable inhibition of ADAM10 (results not shown).
Analysis of TIMP activities against cellular ADAM10 and ADAM17
We utilized the inhibition of CD44 shedding by the highly invasive glioblastoma cell line U251 for the analysis of the efficacy of the various TIMPs against native ADAM10. Initially, in order to establish that shedding was ADAM10-mediated, we used specific siRNA to knockdown ADAM10 and showed that CD44 shedding was compromised (Figure 1a) . Reduced ADAM10 expression was confirmed by analysis of RNA levels by real-time PCR. ADAM17 RNA levels were unaffected by expression of ADAM10 siRNA (Figure 1b) . In addition, Western blotting of lysates from cells transfected with ADAM10 siRNA showed a significant decrease in ADAM10 protein levels compared with mocktransfected cells or those transfected with a non-targeting siRNA control (Figure 1c) . Recombinant ADAM10 propeptide has been shown previously to be a potent inhibitor of ADAM10-mediated shedding of EGFR ligands [24] . We were able to demonstrate that it also inhibited CD44 shedding in our assay, in a dose-dependent manner (Figure 2) , confirming further that ionomycin-stimulated shedding in these cells is ADAM10-mediated.
We assessed the behaviour of the N-TIMPs in comparison with full-length TIMPs in cell-based shedding of CD44 (Figure 3) . In this experiment, we observed 37 % inhibition with TIMP-1 at the highest dose tested (500 nM), but only 6 % inhibition with N-TIMP-1 at the same concentration. As expected, TIMP-3 was an efficient inhibitor of shedding at 500 nM (72 % inhibition; IC 50 ∼ 100 nM), but, surprisingly, N-TIMP-3 had no activity. Full-length TIMP-2 and N-TIMP-2 were also very inefficient inhibitors of shedding (results not shown). We next examined the effects of the N-TIMP mutants with activity towards ADAM17 on ADAM10-mediated shedding. Surprisingly, although no measurable interaction could be obtained for N-TIMP-1 tace against the soluble ADAM10 ectodomain using a small peptide substrate (Table 1) , the mutant showed a dose-dependent inhibition of CD44 shedding. No inhibition of shedding was seen with N-TIMP-2 tace or N-TIMP-4 tace (Figure 4) . In contrast, ADAM17-mediated HB-EGF shedding in an MCF7 model system was efficiently inhibited by both full-length TIMP-3 (results not shown) and N-TIMP-3 ( Figure 5) . At the highest concentration tested (1 µM), N-TIMP-1 tace also inhibited shedding by more than 80 % and N-TIMP-2 tace by nearly 50 % ( Figure 5 ). We confirmed that PMA-stimulated HB-EGF shedding in these cells was ADAM17-mediated by transiently knocking down ADAM17 using specific siRNA, and demonstrated that shedding was compromised ( Figure 6 ). Additionally, ADAM10 propeptide had no inhibitory activity against HB-EGF shedding in these assays (results not shown).
DISCUSSION
Although ADAM10 was discovered several years ago, its physiological substrates remain controversial and elusive. Since it bears sequence similarities to ADAM17 and there is a degree of substrate overlap, the development of inhibitors that distinguish the two activities has been pursued. We originally showed that TIMP-1 can inhibit ADAM10 and, to date, this appears to be a specific activity against this ADAM, compared with TIMP-3 which inhibits ADAMs 10, 12 and 17. Previously, we found that TIMP-1 was a marginally better ADAM10 inhibitor than TIMP-3 [3] . In the present study, we used a lower temperature and a different substrate, and observed that TIMP-3 was a slightly more efficient inhibitor of ADAM10. The measurement of association constants is rather inefficient using these substrates and the margins of error are large, and we conclude that the two TIMPs are of comparable efficacy against the soluble form of ADAM10. To distinguish between ADAM10 and ADAM17, a number of studies have used two low-molecular-mass inhibitors: GW280264X
Both inhibit ADAM10, but only the former inhibits ADAM17 [25, 26] . Recently, the propeptide of ADAM10 has also been used to identify its shedding activity [24] . Systematic modification of the MMP-binding ridge of the inhibitory domain of TIMP-1, TIMP-2 and TIMP-4 [14] [15] [16] [17] [18] has identified key residues that are important for ADAM17 specificity. In the present study, we aimed to investigate whether the mutant TIMPs would inhibit ADAM10 in biochemical and cell-based assays. We first wanted to establish whether the inhibitory domains of TIMPs (N-TIMPs) were sufficient for ADAM10 inhibition. Kinetic analysis clearly showed that even at high concentrations (500 nM) none of the four N-TIMPs was able to inhibit ADAM10 enzymatic activity. When the fulllength inhibitors were tested using the same kinetic assay we found that TIMP-1 and TIMP-3 were able to inhibit ADAM10 with K i values of 0.1 and 0.5 nM respectively. In comparison, we have shown previously that binding of TIMP-1, TIMP-2 or TIMP-3 to MMP 2 was markedly reduced by loss of the C-terminal domain [27, 29] . We also found that the extracatalytic domains of ADAM17 interfered with TIMP-3 binding [14] , implying interactions outside the TIMP N-terminal ridgecatalytic cleft sites defined in the existing TIMP-MMP structures [11, 12] .
In our previous studies, we have identified the key residues of N-TIMPs that are essential for ADAM17 specificity. In the present study, we tested the N-TIMP-1, N-TIMP-2 and N-TIMP-4 variants previously designed and shown to be potent inhibitors of ADAM17 against ADAM10. These N-TIMP variants were not able to form stable complexes with soluble recombinant ADAM10 and it was not possible to obtain any values either for the binding affinity or the association rates of these inhibitors with the enzyme.
We used a cell-based shedding assay to establish whether the findings obtained from our kinetic studies of soluble ADAM10 reflected TIMP inhibitory activity against the native enzyme. Shedding of the hyaluronan receptor, CD44, from the surface of U251 cells can be stimulated by short incubations with ionomycin [30] . Silencing of ADAM10 by siRNA significantly knocked down both RNA and protein expression and additionally inhibited stimulated shedding. The result indicates that this shedding activity is ADAM10-specific. Dose-dependent inhibition of stimulated CD44 shedding using recombinant ADAM10 propeptide confirmed further the role of ADAM10.
Broadly speaking, the data obtained from our cell-based assay agreed with that obtained in our kinetic studies. Both full-length TIMP-1 and TIMP-3 inhibited CD44 shedding, although TIMP-3 was consistently more efficient than TIMP-1. N-TIMP-1 had a very low level of inhibitory activity, whereas N-TIMP-3 was totally unable to inhibit shedding at any concentration tested. Surprisingly, the N-TIMP-1 variant designed previously to be a potent inhibitor of ADAM17, N-TIMP-1 tace , showed a doseresponsive inhibition of CD44 shedding. However, N-TIMP-2 tace and N-TIMP-4 tace remained ineffective. We conclude that interaction of ADAM10 with the cell-bound CD44 substrate modified the ability of N-TIMP-1 tace to inhibit shedding. In contrast, N-TIMP-3 and the N-TIMP tace variants were efficient inhibitors of ADAM17-mediated HB-EGF shedding, confirming that the mechanism by which TIMPs inhibit ADAM10 activity differs from that of ADAM17. It is clear that, unlike ADAM17, for ADAM10 inhibition, the C-terminal domain of TIMP-3 is indispensable for the interaction with the enzyme. We may speculate that efficient TIMP-3 inhibition of native ADAM10 depends on a specific alignment or configuration of enzyme, inhibitor and substrate that requires the C-terminal domain of TIMP-3. This can probably be attributed to the spatial distribution of TIMP-3 in the cell system, possibly involving its sequestration to the ECM (extracellular matrix). Yu et al. [28] showed that TIMP-3 bound to glycosaminoglycans within the ECM. Furthermore, heparin and heparin sulfate have been shown to enhance the activity of TIMP-3 against MMP-2 [29], MMP-13 and ADAM17 (P. Dodds, M.H. Lee and G. Murphy, unpublished work). Chondroitin 6-sulfate and heparan sulfate also enhance TIMP-3 binding to ADAMTS4 [31] (G. Wayne, A. Amour and G. Murphy, unpublished work). Our recent study identified motifs in both the N-terminal and C-terminal domains of TIMP-3 that are essential for ECM binding [32] . The data from the cellbased assays of ADAM activity suggest that soluble TIMPs are less efficient for ADAM10 inhibition than ECM-bound TIMPs. However, the results from our kinetic assays using a fluorigenic peptide indicate that the C-terminal domains of TIMP-1 and TIMP-3 must also interact directly with the ectodomain of soluble ADAM10 for efficient inhibition.
Overall, these results suggest that C-terminal domain interactions play an important role in ADAM10 inhibition. We have been unable to prepare isolated recombinant C-terminal subdomains to assess their independent ability to bind to ADAM10.
The difference in the inhibitory behaviour of full-length and C-terminally truncated TIMPs with respect to ADAM17 and ADAM10 could pave the way to the development of selective inhibitors. Further investigation is needed in order to establish which epitopes of the C-terminal domains of TIMPs are crucial for ADAM10 inhibition in order to understand the TIMP-ADAM10 inhibition mechanism.
